摘要
背景与目的观察厄洛替尼一线治疗晚期非小细胞肺癌的疗效和毒副反应。方法28例病理确诊的不愿或不能接受传统细胞毒性药物化疗的非小细胞肺癌患者,口服厄洛替尼150mg,每日1次,持续用药直至肿瘤进展或出现不可耐受的毒副反应。结果厄洛替尼的有效率为28.6%,疾病控制率为60.7%,症状改善率为53.6%,中位无进展生存期为3.2个月(95%CI:0.815-5.585),中位生存期为9.6个月(95%CI:7.179-12.021),1年生存率为32.1%,有皮疹患者的疗效优于无皮疹患者。本组多为I、II级毒副反应,常见的毒副反应为皮疹(46.4%)、腹泻(32.1%)、皮肤干燥(25.0%)、厌食(17.9%)、疲乏(10.7%)和转氨酶升高(7.1%)。结论对不愿或不能接受传统细胞毒性药物化疗的非小细胞肺癌患者,厄洛替尼为其提供了另一个选择。
Background and objective To evaluate the efficacy and toxicity of erlotinib as the first-line therapy for advanced non-small cell lung cancer （NSCLC）.Methods A total of 28 pathologically-confirmed NSCLC patients who could not receive willingly or tolerate traditional cytotoxic drugs chemotherapy were enrolled.Erlotinib was orally administered 150 mg daily until disease progression or the occurrence of intolerable toxicity.Results Among a total of 28 patients,the objective response rate （ORR） of erlotinib was 28.6%.The disease control rate （DCR） was 60.7%.The rate of symptom relief was 53.6%.The median progression free survival （PFS） was 3.2 （95%CI：0.851-5.585） months.The median overall survival （OS） was 9.6 （95%CI：7.179-12.021） months.One-year survival rate was 32.1%.The therapeutic effect was better in patients with rash.Most of the toxicities were grade I and grade II toxicity.The most common adverse events were rash （46.4%）,diarrhea （32.1%）,skin dry （25.0%）,anorexia（17.9%）,fatigue （10.7%） and increased transaminase （7.1%）.Conclusion Erlotinib provided another choice for the patients who could not willingly receive or tolerate chemotherapy.
出处
《中国肺癌杂志》
CAS
2009年第12期1282-1286,共5页
Chinese Journal of Lung Cancer
关键词
厄洛替尼
肺肿瘤
一线治疗
Erlotinib
Lung neoplasms
First-line therapy
